肝细胞癌作为原发性肝癌最主要的病理类型，具有恶性程度高、起病隐匿等特点，是严重威胁人类健康的消化系统恶性肿瘤之一。肿瘤细胞的代谢重编程是其区别于正常细胞的核心生物学特征，其中糖代谢异常尤为突出。肝癌细胞多依赖有氧糖酵解及其他异常糖代谢途径获取能量与生物合成前体，进而维持其无限增殖、侵袭及转移等恶性表型。因此，以糖代谢核心酶与关键通路为靶点进行干预，已成为肝细胞癌治疗研究的重要方向。中药因其成分多样、作用靶点广泛、不良反应小等优势，在靶向调控肿瘤糖代谢方面展现出巨大潜力。系统综述中药通过干预糖代谢关键环节抑制肝细胞癌的药理机制，可为研发新型抗肝细胞癌药物提供理论依据与研究思路。

Hepatocellular carcinoma (HCC), the most common pathological type of primary liver cancer, is characterized by high malignancy and insidious onset, and is one of the malignant tumors of the digestive system that seriously threaten human health. Metabolic reprogramming of tumor cells is a core biological feature that distinguishes them from normal cells, with abnormal glucose metabolism being particularly prominent. Hepatocellular carcinoma cells often rely on aerobic glycolysis and other abnormal glucose metabolic pathways to obtain energy and biosynthetic precursors, thereby maintaining their malignant phenotypes such as unlimited proliferation, invasion, and metastasis. Therefore, targeting the core enzymes and key pathways of glucose metabolism for intervention has become an important direction in the treatment research of hepatocellular carcinoma. Traditional Chinese medicine, with its advantages of diverse components, wide range of action targets, and few adverse reactions, has shown great potential in targeting and regulating tumor glucose metabolism. A systematic review of the pharmacological mechanisms by which traditional Chinese medicine inhibits hepatocellular carcinoma through intervention in key links of glucose metabolism can provide theoretical basis and research ideas for the development of new anti-HCC drugs.

R285.5

国家自然科学基金资助项目（32304793）；黑龙江省自然科学基金计划项目（LH2023H072）；黑龙江省自然科学基金计划项目（PL2024H244）